Off-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice
- PMID: 26544580
- DOI: 10.1097/QAD.0000000000000819
Off-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice
Abstract
Maraviroc (MVC) is not approved for HIV-1-infected paediatric patients. This is the first assessment of the use of MVC-based salvage therapy in vertically HIV-1-infected paediatric patients in clinical settings. The results suggest that MVC-based salvage therapy is useful in children and adolescents with extensive resistance profile leading to maintained virological suppression in up to 88% of the patients with CCR5-tropic virus. The likelihood of treatment success might increase when MVC is combined with other active drugs.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical